Login to Your Account



Clinic Roundup


Friday, October 26, 2012
• Durata Therapeutics Inc., of Morristown, N.J., reached its target enrollment for DISCOVER 2 (Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response), the second global Phase III trial of Durata's lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription